CGEM · Cullinan Therapeutics, Inc.
$21.68
+0.30 (+1.40%)
At close · Aug 21
Market Cap
$1.38B
Shares
64.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.68
Open$21.72
Day$21.40–22.10
52W close$5.75–22.52
Avg vol 30d637K
Short int10.3M · 15.9% float · 19.2d
Short vol24%
DataJan 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+56%
above
Price vs 50-day avg
+22%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+36%
trailing
YTD return
+109%
this year
Relative strength
+24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.93% of float · ▼ -0.3% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
183 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−255%
Y/Y
Free cash flow
$-175.8M
Balance sheet
$88.3M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+56%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $18 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.93% of float · ▼ -0.3% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
183 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $22 · 95%
Range high $23
vs 200-day avg +56%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGEM
this stock
Cullinan Therapeutics, Inc.
|
$1.38B | +109.5% | -100.0% | — | 15.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGEM | +6.6% | +26.8% | +35.6% | +31.4% | +109.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +8.6% | +23.5% | +24.4% | +29.3% | +97.6% |
Key facts
CIK
1789972
CUSIP
230031106
13F (30d)
171 filings
169 filers
Visit website
Investor relations